Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: Drugs targeting β-amyloid and tau protein

Francesco Panza, Vincenzo Solfrizzi, Vincenza Frisardi, Bruno P. Imbimbo, Cristiano Capurso, Alessia D'Introno, Anna M. Colacicco, Davide Seripa, Gianluigi Vendemiale, Antonio Capurso, Alberto Pilotto

Research output: Contribution to journalArticle

Abstract

Drugs currently used to treat Alzheimer's Disease (AD) have limited therapeutic value and do not affect the main neuropathological hallmarks of the disease, i.e., senile plaques and neurofibrillar tangles. Senile plaques are mainly formed of β-amyloid (Aβ), a 42-aminoacid peptide. Neurofibrillar tangles are composed of paired helical filaments of hyperphosphorylated tau protein. New, potentially disease-modifying, therapeutic approaches are targeting Aβ and tau protein. Drugs directed against Aβ include active and passive immunization, that have been found to accelerate Aβ clearance from the brain. The most developmentally advanced monoclonal antibody directly targeting Aβ is bapineuzumab, now being studied in a large Phase III clinical trial. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. The discovery of inhibitors of β-secretase, the enzyme that regulates the first step of the amyloidogenic metabolism of APP, has been revealed to be particularly difficult due to inherent medicinal chemistry problems, and only one compound (CTS-21166) has reached clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), now in Phase III clinical development. Compounds that stimulate α-secretase, the enzyme responsible for the non-amyloidogenic metabolism of APP, are also being developed, and one of them, EHT-0202, has recently entered Phase II testing. Potent inhibitors of Aβ aggregation have also been identified, and one of such compounds, PBT-2, has provided encouraging neuropsychological results in a recently completed Phase II study. Therapeutic approaches directed against tau protein include inhibitors of glycogen synthase kinase-3 (GSK-3), the enzyme responsible for tau phosphorylation and tau protein aggregation inhibitors. NP-12, a promising GSK-3 inhibitor, is being tested in a Phase II study, and methylthioninium chloride, a tau protein aggregation inhibitor, has given initial encouraging results in a 50-week study. With all these approaches on their way, the hope for disease-modifying therapy in this devastating disease may become a reality in the next 5 years.

Original languageEnglish
Pages (from-to)386-406
Number of pages21
JournalAging clinical and experimental research
Volume21
Issue number6
Publication statusPublished - Dec 2009

Fingerprint

Amyloidogenic Proteins
tau Proteins
Drug Delivery Systems
Neurotransmitter Agents
Alzheimer Disease
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Glycogen Synthase Kinase 3
Amyloid Plaques
Enzymes
Serum Amyloid A Protein
Phase III Clinical Trials
Passive Immunization
Pharmaceutical Chemistry
Methylene Blue
Enzyme Inhibitors
Therapeutics
Amyloid
Pharmaceutical Preparations

Keywords

  • α-secretase activators
  • β-amyloid
  • β-secretase inhibitors
  • γ-secretase inhibitors
  • γ-secretase modulators
  • Aβ aggregation inhibitors
  • Active immunotherapy
  • Alzheimer's disease
  • Passive immunotherapy

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B. P., Capurso, C., D'Introno, A., ... Pilotto, A. (2009). Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: Drugs targeting β-amyloid and tau protein. Aging clinical and experimental research, 21(6), 386-406.

Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease : Drugs targeting β-amyloid and tau protein. / Panza, Francesco; Solfrizzi, Vincenzo; Frisardi, Vincenza; Imbimbo, Bruno P.; Capurso, Cristiano; D'Introno, Alessia; Colacicco, Anna M.; Seripa, Davide; Vendemiale, Gianluigi; Capurso, Antonio; Pilotto, Alberto.

In: Aging clinical and experimental research, Vol. 21, No. 6, 12.2009, p. 386-406.

Research output: Contribution to journalArticle

Panza, F, Solfrizzi, V, Frisardi, V, Imbimbo, BP, Capurso, C, D'Introno, A, Colacicco, AM, Seripa, D, Vendemiale, G, Capurso, A & Pilotto, A 2009, 'Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: Drugs targeting β-amyloid and tau protein', Aging clinical and experimental research, vol. 21, no. 6, pp. 386-406.
Panza, Francesco ; Solfrizzi, Vincenzo ; Frisardi, Vincenza ; Imbimbo, Bruno P. ; Capurso, Cristiano ; D'Introno, Alessia ; Colacicco, Anna M. ; Seripa, Davide ; Vendemiale, Gianluigi ; Capurso, Antonio ; Pilotto, Alberto. / Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease : Drugs targeting β-amyloid and tau protein. In: Aging clinical and experimental research. 2009 ; Vol. 21, No. 6. pp. 386-406.
@article{58f3f23a08d84b42847b3b9800a9623a,
title = "Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: Drugs targeting β-amyloid and tau protein",
abstract = "Drugs currently used to treat Alzheimer's Disease (AD) have limited therapeutic value and do not affect the main neuropathological hallmarks of the disease, i.e., senile plaques and neurofibrillar tangles. Senile plaques are mainly formed of β-amyloid (Aβ), a 42-aminoacid peptide. Neurofibrillar tangles are composed of paired helical filaments of hyperphosphorylated tau protein. New, potentially disease-modifying, therapeutic approaches are targeting Aβ and tau protein. Drugs directed against Aβ include active and passive immunization, that have been found to accelerate Aβ clearance from the brain. The most developmentally advanced monoclonal antibody directly targeting Aβ is bapineuzumab, now being studied in a large Phase III clinical trial. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. The discovery of inhibitors of β-secretase, the enzyme that regulates the first step of the amyloidogenic metabolism of APP, has been revealed to be particularly difficult due to inherent medicinal chemistry problems, and only one compound (CTS-21166) has reached clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), now in Phase III clinical development. Compounds that stimulate α-secretase, the enzyme responsible for the non-amyloidogenic metabolism of APP, are also being developed, and one of them, EHT-0202, has recently entered Phase II testing. Potent inhibitors of Aβ aggregation have also been identified, and one of such compounds, PBT-2, has provided encouraging neuropsychological results in a recently completed Phase II study. Therapeutic approaches directed against tau protein include inhibitors of glycogen synthase kinase-3 (GSK-3), the enzyme responsible for tau phosphorylation and tau protein aggregation inhibitors. NP-12, a promising GSK-3 inhibitor, is being tested in a Phase II study, and methylthioninium chloride, a tau protein aggregation inhibitor, has given initial encouraging results in a 50-week study. With all these approaches on their way, the hope for disease-modifying therapy in this devastating disease may become a reality in the next 5 years.",
keywords = "α-secretase activators, β-amyloid, β-secretase inhibitors, γ-secretase inhibitors, γ-secretase modulators, Aβ aggregation inhibitors, Active immunotherapy, Alzheimer's disease, Passive immunotherapy",
author = "Francesco Panza and Vincenzo Solfrizzi and Vincenza Frisardi and Imbimbo, {Bruno P.} and Cristiano Capurso and Alessia D'Introno and Colacicco, {Anna M.} and Davide Seripa and Gianluigi Vendemiale and Antonio Capurso and Alberto Pilotto",
year = "2009",
month = "12",
language = "English",
volume = "21",
pages = "386--406",
journal = "Aging clinical and experimental research",
issn = "1594-0667",
publisher = "Springer International Publishing AG",
number = "6",

}

TY - JOUR

T1 - Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease

T2 - Drugs targeting β-amyloid and tau protein

AU - Panza, Francesco

AU - Solfrizzi, Vincenzo

AU - Frisardi, Vincenza

AU - Imbimbo, Bruno P.

AU - Capurso, Cristiano

AU - D'Introno, Alessia

AU - Colacicco, Anna M.

AU - Seripa, Davide

AU - Vendemiale, Gianluigi

AU - Capurso, Antonio

AU - Pilotto, Alberto

PY - 2009/12

Y1 - 2009/12

N2 - Drugs currently used to treat Alzheimer's Disease (AD) have limited therapeutic value and do not affect the main neuropathological hallmarks of the disease, i.e., senile plaques and neurofibrillar tangles. Senile plaques are mainly formed of β-amyloid (Aβ), a 42-aminoacid peptide. Neurofibrillar tangles are composed of paired helical filaments of hyperphosphorylated tau protein. New, potentially disease-modifying, therapeutic approaches are targeting Aβ and tau protein. Drugs directed against Aβ include active and passive immunization, that have been found to accelerate Aβ clearance from the brain. The most developmentally advanced monoclonal antibody directly targeting Aβ is bapineuzumab, now being studied in a large Phase III clinical trial. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. The discovery of inhibitors of β-secretase, the enzyme that regulates the first step of the amyloidogenic metabolism of APP, has been revealed to be particularly difficult due to inherent medicinal chemistry problems, and only one compound (CTS-21166) has reached clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), now in Phase III clinical development. Compounds that stimulate α-secretase, the enzyme responsible for the non-amyloidogenic metabolism of APP, are also being developed, and one of them, EHT-0202, has recently entered Phase II testing. Potent inhibitors of Aβ aggregation have also been identified, and one of such compounds, PBT-2, has provided encouraging neuropsychological results in a recently completed Phase II study. Therapeutic approaches directed against tau protein include inhibitors of glycogen synthase kinase-3 (GSK-3), the enzyme responsible for tau phosphorylation and tau protein aggregation inhibitors. NP-12, a promising GSK-3 inhibitor, is being tested in a Phase II study, and methylthioninium chloride, a tau protein aggregation inhibitor, has given initial encouraging results in a 50-week study. With all these approaches on their way, the hope for disease-modifying therapy in this devastating disease may become a reality in the next 5 years.

AB - Drugs currently used to treat Alzheimer's Disease (AD) have limited therapeutic value and do not affect the main neuropathological hallmarks of the disease, i.e., senile plaques and neurofibrillar tangles. Senile plaques are mainly formed of β-amyloid (Aβ), a 42-aminoacid peptide. Neurofibrillar tangles are composed of paired helical filaments of hyperphosphorylated tau protein. New, potentially disease-modifying, therapeutic approaches are targeting Aβ and tau protein. Drugs directed against Aβ include active and passive immunization, that have been found to accelerate Aβ clearance from the brain. The most developmentally advanced monoclonal antibody directly targeting Aβ is bapineuzumab, now being studied in a large Phase III clinical trial. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. The discovery of inhibitors of β-secretase, the enzyme that regulates the first step of the amyloidogenic metabolism of APP, has been revealed to be particularly difficult due to inherent medicinal chemistry problems, and only one compound (CTS-21166) has reached clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), now in Phase III clinical development. Compounds that stimulate α-secretase, the enzyme responsible for the non-amyloidogenic metabolism of APP, are also being developed, and one of them, EHT-0202, has recently entered Phase II testing. Potent inhibitors of Aβ aggregation have also been identified, and one of such compounds, PBT-2, has provided encouraging neuropsychological results in a recently completed Phase II study. Therapeutic approaches directed against tau protein include inhibitors of glycogen synthase kinase-3 (GSK-3), the enzyme responsible for tau phosphorylation and tau protein aggregation inhibitors. NP-12, a promising GSK-3 inhibitor, is being tested in a Phase II study, and methylthioninium chloride, a tau protein aggregation inhibitor, has given initial encouraging results in a 50-week study. With all these approaches on their way, the hope for disease-modifying therapy in this devastating disease may become a reality in the next 5 years.

KW - α-secretase activators

KW - β-amyloid

KW - β-secretase inhibitors

KW - γ-secretase inhibitors

KW - γ-secretase modulators

KW - Aβ aggregation inhibitors

KW - Active immunotherapy

KW - Alzheimer's disease

KW - Passive immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=77649256879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649256879&partnerID=8YFLogxK

M3 - Article

C2 - 20154508

AN - SCOPUS:77649256879

VL - 21

SP - 386

EP - 406

JO - Aging clinical and experimental research

JF - Aging clinical and experimental research

SN - 1594-0667

IS - 6

ER -